Background: Assessing the Brazilian clinical practice in patients with acute coronary syndrome, in public and private hospitals to identify gaps in the incorporation of clinical interventions with proven benefit.Objective: To develop a registry of patients diagnosed with acute coronary syndrome to assess demographics, morbidity, mortality, and standard practice in the care of this condition. Besides, to assess the prescription of evidence-based interventions such as aspirin, statins, beta blockers and reperfusion, among others.Methods: Registry-type prospective observational study intended to document hospital clinical practices of acute coronary syndrome in public and private hospitals in Brazil. In addition, longitudinal follow-up will be held until discharge and measurement of mortality and occurrence of serious events at 30 days, 6 and 12 months.Results: The findings will be presented one year after the start of collection (September 2011), and consolidated after a meeting with the population to discuss the objectives sought.
Conclusion
IntroductionRecent data from the World Health Organization reveal that cardiovascular diseases, particularly acute myocardial infarction (AMI), are the main cause of disability and morbidity and mortality in both sexes, both in Brazil and in the world 1-3 .Since it is a major public health problem, the search for interventions that have proven benefits in reducing the incidence of this disease and its complications is a priority. Interventions with proven benefit in reducing major cardiovascular events include drugs such as aspirin, thrombolytics and antiplatelet agents at hospital admission, converting enzyme inhibitors, statins and beta blockers at discharge. These have reduced the relative risk ranging from 6.5 to 25% in previous studies [4][5][6][7][8] . Previous records showed that use of these interventions in the setting of acute coronary syndromes (ACS) is still suboptimal, suggesting, upon admission, aspirin usage rates ranging from 91 to 92%, and upon discharge, ranging between 90 and 95%, statin usage upon discharge ranging between 26 and 57%, and beta-blocker usage upon discharge in less than 63 to 77% of patients [9][10][11][12][13][14] . The assessment of its occurrence, through a national registry for controlled collection recently implemented, can thus document the clinical practice in the treatment of patients with ACS, whether hospitalized in public and/or private hospitals in Brazil.
MethodsThe registry represents a documentation project of the current clinical practice of service to ACS in Brazil aiming to identify the incorporation of evidence into the clinical practice of treatment of this disease, involving public and private hospitals. Additionally, there will be longitudinal follow-up of patients until their discharge from hospital, besides checking mortality within 30 days, 6 and 12 months.
A. DesignACS patients treated in public and private hospitals will be compiled to define data related to demographic characteristics, morbidity, mortalit...